|
1
|
Liu J, Gu J, Feng Z, Yang Y, Zhu N, Lu W
and Qi F: Both HDAC5 and HDAC6 are required for the proliferation
and metastasis of melanoma cells. J Transl Med. 14:72016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agarwala SS: Current systemic therapy for
metastatic melanoma. Expert Rev Anticancer Ther. 9:587–595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC Melanoma Staging and
Classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu Z, Liu W and Gotlieb V: The rapidly
evolving therapies for advanced melanoma - Towards immunotherapy,
molecular targeted therapy, and beyond. Crit Rev Oncol Hematol.
99:91–99. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang J, Liu D, Huang Y, Gao Y and Qian S:
Biopharmaceutics classification and intestinal absorption study of
apigenin. Int J Pharm. 436:311–317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ding SM, Zhang ZH, Song J, Cheng XD, Jiang
J and Jia XB: Enhanced bioavailability of apigenin via preparation
of a carbon nanopowder solid dispersion. Int J Nanomedicine.
9:2327–2333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arsić I, Tadić V, Vlaović D, Homšek I,
Vesić S, Isailović G and Vuleta G: Preparation of novel
apigenin-enriched, liposomal and non-liposomal, antiinflammatory
topical formulations as substitutes for corticosteroid therapy.
Phytother Res. 25:228–233. 2011.PubMed/NCBI
|
|
8
|
Al Shaal L, Shegokar R and Müller RH:
Production and characterization of antioxidant apigenin
nanocrystals as a novel UV skin protective formulation. Int J
Pharm. 420:133–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Patel D, Shukla S and Gupta S: Apigenin
and cancer chemoprevention: Progress, potential and promise
(Review). Int J Oncol. 30:233–245. 2007.PubMed/NCBI
|
|
10
|
Shi MD, Shiao CK, Lee YC and Shih YW:
Apigenin, a dietary flavonoid, inhibits proliferation of human
bladder cancer T-24 cells via blocking cell cycle progression and
inducing apoptosis. Cancer Cell Int. 15:332015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suh YA, Jo SY, Lee HY and Lee C:
Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor
tyrosine kinases by apigenin circumvent taxol resistance in ovarian
cancer cells. Int J Oncol. 46:1405–1411. 2015.PubMed/NCBI
|
|
12
|
Shukla S, Bhaskaran N, Babcook MA, Fu P,
Maclennan GT and Gupta S: Apigenin inhibits prostate cancer
progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.
Carcinogenesis. 35:452–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shukla S, Kanwal R, Shankar E, Datt M,
Chance MR, Fu P, MacLennan GT and Gupta S: Apigenin blocks IKKα
activation and suppresses prostate cancer progression. Oncotarget.
6:31216–31232. 2015.PubMed/NCBI
|
|
14
|
Scherbakov AM and Andreeva OE: Apigenin
inhibits growth of breast cancer cells: The role of ERα and
HER2/neu. Acta naturae. 7:133–139. 2015.PubMed/NCBI
|
|
15
|
Seo HS, Ku JM, Choi HS, Woo JK, Jang BH,
Go H, Shin YC and Ko SG: Apigenin induces caspase-dependent
apoptosis by inhibiting signal transducer and activator of
transcription 3 signaling in HER2-overexpressing SKBR3 breast
cancer cells. Mol Med Rep. 12:2977–2984. 2015.PubMed/NCBI
|
|
16
|
Caltagirone S, Rossi C, Poggi A,
Ranelletti FO, Natali PG, Brunetti M, Aiello FB and Piantelli M:
Flavonoids apigenin and quercetin inhibit melanoma growth and
metastatic potential. Int J Cancer. 87:595–600. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye Y, Chou GX, Wang H, Chu JH and Yu ZL:
Flavonoids, apigenin and icariin exert potent melanogenic
activities in murine B16 melanoma cells. Phytomedicine. 18:32–35.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pang W, Leng X, Lu H, Yang H, Song N, Tan
L, Jiang Y and Guo C: Depletion of intracellular zinc induces
apoptosis of cultured hippocampal neurons through suppression of
ERK signaling pathway and activation of caspase-3. Neurosci Lett.
552:140–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan TO, Rittenhouse SE and Tsichlis PN:
AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase
activation by phosphoinositide-dependent phosphorylation. Annu Rev
Biochem. 68:965–1014. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lopez RF, Lange N, Guy R and Bentley MV:
Photodynamic therapy of skin cancer: Controlled drug delivery of
5-ALA and its esters. Adv Drug Deliv Rev. 56:77–94. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eggler AL, Gay KA and Mesecar AD:
Molecular mechanisms of natural products in chemoprevention:
Induction of cytoprotective enzymes by Nrf2. Mol Nutr Food Res.
52:(Suppl 1). S84–S94. 2008.PubMed/NCBI
|
|
23
|
Shukla S and Gupta S: Apigenin: A
promising molecule for cancer prevention. Pharm Res. 27:962–978.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim MA, Kang K, Lee HJ, Kim M, Kim CY and
Nho CW: Apigenin isolated from Daphne genkwa Siebold et
Zucc. inhibits 3T3-L1 preadipocyte differentiation through a
modulation of mitotic clonal expansion. Life Sci. 101:64–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang Y, Ji P, Liu J, Broaddus RR, Xue F
and Zhang W: Centrosome-associated regulators of the
G2/M checkpoint as targets for cancer therapy. Mol
Cancer. 8:82009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dash BC and El-Deiry WS: Phosphorylation
of p21 in G2/M promotes cyclin B-Cdc2 kinase activity.
Mol Cell Biol. 25:3364–3387. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Stewart ZA, Westfall MD and Pietenpol JA:
Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol
Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee Y, Sung B, Kang YJ, Kim DH, Jang JY,
Hwang SY, Kim M, Lim HS, Yoon JH, Chung HY, et al: Apigenin-induced
apoptosis is enhanced by inhibition of autophagy formation in
HCT116 human colon cancer cells. Int J Oncol. 44:1599–1606.
2014.PubMed/NCBI
|
|
29
|
Zhang L, Cheng X, Gao Y, Zheng J, Xu Q,
Sun Y, Guan H, Yu H and Sun Z: Apigenin induces autophagic cell
death in human papillary thyroid carcinoma BCPAP cells. Food Funct.
6:3464–3472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, Wu J,
Xu X, Xu X, Qin J and Xie L: Apigenin promotes apoptosis, inhibits
invasion and induces cell cycle arrest of T24 human bladder cancer
cells. Cancer Cell Int. 13:542013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee SR, Park JH, Park EK, Chung CH, Kang
SS and Bang OS: Akt-induced promotion of cell-cycle progression at
G2/M phase involves upregulation of NF-Y binding
activity in PC12 cells. J Cell Physiol. 205:270–277. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin HP, Jiang SS and Chuu CP: Caffeic acid
phenethyl ester causes p21Cip1 induction, Akt signaling
reduction, and growth inhibition in PC-3 human prostate cancer
cells. PLoS One. 7:e312862012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Erdogan S, Doganlar O, Doganlar ZB,
Serttas R, Turkekul K, Dibirdik I and Bilir A: The flavonoid
apigenin reduces prostate cancer CD44+ stem cell
survival and migration through PI3K-Akt/NF-κB signaling. Life Sci.
162:77–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Renehan AG, Booth C and Potten CS: What is
apoptosis, and why is it important? BMJ. 322:1536–1538. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hassen S, Ali N and Chowdhury P: Molecular
signaling mechanisms of apoptosis in hereditary non-polyposis
colorectal cancer. World J Gastrointest Pathophysiol. 3:71–79.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boulares AH, Yakovlev AG, Ivanova V,
Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose)
polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP
mutant increases rates of apoptosis in transfected cells. J Biol
Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Seo HS, Choi HS, Kim SR, Choi YK, Woo SM,
Shin I, Woo JK, Park SY, Shin YC and Ko SG: Apigenin induces
apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3
and NFκB signaling in HER2-overexpressing breast cancer cells. Mol
Cell Biochem. 366:319–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shukla S, Fu P and Gupta S: Apigenin
induces apoptosis by targeting inhibitor of apoptosis proteins and
Ku70-Bax interaction in prostate cancer. Apoptosis. 19:883–894.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Das S, Das J, Samadder A, Boujedaini N and
Khuda-Bukhsh AR: Apigenin-induced apoptosis in A375 and A549 cells
through selective action and dysfunction of mitochondria. Exp Biol
Med (Maywood). 237:1433–1448. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Choi KY, Chang K, Pickel JM, Badger JD II
and Roche KW: Expression of the metabotropic glutamate receptor 5
(mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci
USA. 108:15219–15224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Khan AJ, Wall B, Ahlawat S, Green C,
Schiff D, Mehnert JM, Goydos JS, Chen S and Haffty BG: Riluzole
enhances ionizing radiation-induced cytotoxicity in human melanoma
cells that ectopically express metabotropic glutamate receptor 1 in
vitro and in vivo. Clin Cancer Res. 17:1807–1814. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee HJ, Wall BA, Wangari-Talbot J, Shin
SS, Rosenberg S, Chan JLK, Namkoong Jin, Goydos JS and Chen S:
Glutamatergic pathway targeting in melanoma: Single-agent and
combinatorial therapies. Clin Cancer Res. 17:7080–7092. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gelb T, Pshenichkin S, Hathaway HA,
Grajkowska E, Dalley CB, Wolfe BB and Wroblewski JT: Atypical
signaling of metabotropic glutamate receptor 1 in human melanoma
cells. Biochem Pharmacol. 98:182–189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lee HJ, Wall BA, Wangari-Talbot J and Chen
S: Regulation of mGluR1 expression in human melanocytes and
melanoma cells. Biochim Biophys Acta. 1819:1123–1131. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song Z, He CD, Liu J, Sun C, Lu P, Li L,
Gao L, Zhang Y, Xu Y, Shan L, et al: Blocking glutamate-mediated
signalling inhibits human melanoma growth and migration. Exp
Dermatol. 21:926–931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tanimura S, Uchiyama A, Watanabe K,
Yasunaga M, Inada Y, Kawabata T, Iwashita K, Noda S, Ozaki K and
Kohno M: Blockade of constitutively activated ERK signaling
enhances cytotoxicity of microtubule-destabilizing agents in tumor
cells. Biochem Biophys Res Commun. 378:650–655. 2009. View Article : Google Scholar : PubMed/NCBI
|
